The decision to discontinue screening for carnitine uptake disorder in New Zealand

When screening for carnitine uptake disorder (CUD), the New Zealand (NZ) newborn screening (NBS) service identified infants as screen‐positive if they had initial and repeat free carnitine (C0) levels of less than 5.0 μmol/L. Since 2006, the NBS service has identified two infants with biochemical and genetic features consistent with neonatal CUD and nine mothers with features consistent with maternal CUD. A review of the literature suggests that these nine women reflect less than half the true prevalence and that CUD is relatively common. However, the NZ results (two infants) suggest a very low sensitivity and positive predictive value of NBS. While patients presenting with significant disease due to CUD are well described, the majority of adults with CUD are asymptomatic. Nonetheless, treatment with high‐dose oral L‐carnitine is recommended. Compliance with oral L‐carnitine is likely to be poor long term. This may represent a specific risk as treatment could repress the usual compensatory mechanisms seen in CUD, such that a sudden discontinuation of treatment may be dangerous. L‐carnitine is metabolized to trimethylamine‐N‐oxide (TMAO) and treated patients have extremely high plasma TMAO levels. TMAO is an independent risk factor for atherosclerosis and, thus, caution should be exercised regarding long‐term treatment with high‐dose carnitine of asymptomatic patients who may have a biochemical profile without disease. Due to these concerns, the NZ Newborn Metabolic Screening Programme (NMSP) initiated a review via a series of advisory and governance committees and decided to discontinue screening for CUD.

• Publication year

  2018

• Venue

  Journal of Inherited Metabolic Disease

• Publication date

  2018-04-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/jimd.12030PMID 30740730
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genetics of hypertrophic cardiomyopathy: A review of current state

  2018cited by this paper
• The decision to discontinue screening for carnitine uptake disorder in New Zealand

  2018cited by this paper
• A systematic review and meta-analysis

  2017cited by this paper
• Primary Carnitine Deficiency: Is Foetal Development Affected and Can Newborn Screening Be Improved?

  2017influential reference
• Exome sequencing identifies primary carnitine deficiency in a family with cardiomyopathy and sudden death

  2017cited by this paper
• Neonatal Screening for Primary Carnitine Deficiency: Lessons Learned from the Faroe Islands

  2017cited by this paper
• Trimethylamine N-oxide and prognosis in acute heart failure

  2016cited by this paper
• The gut microbiome, diet, and links to cardiometabolic and chronic disorders

  2016cited by this paper
• Chronic Oral L-Carnitine Supplementation Drives Marked Plasma TMAO Elevations in Patients with Organic Acidemias Despite Dietary Meat Restrictions.

  2016cited by this paper
• Carnitine levels in skeletal muscle, blood, and urine in patients with primary carnitine deficiency during intermission of L-carnitine supplementation.

  2015cited by this paper
• Identification of SLC22A5 Gene Mutation in a Family with Carnitine Uptake Defect

  2015cited by this paper
• Statin treatment non-adherence and discontinuation: clinical implications and potential solutions.

  2014cited by this paper
• Primary Carnitine deficiency in the Faroe Islands: health and cardiac status in 76 adult patients diagnosed by screening

  2014cited by this paper
• Plasma choline metabolites and colorectal cancer risk in the Women's Health Initiative Observational Study.

  2014cited by this paper
• The contributory role of gut microbiota in cardiovascular disease.

  2014cited by this paper
• Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk.

  2013cited by this paper
• Neuropsychological outcomes in fatty acid oxidation disorders: 85 cases detected by newborn screening.

  2013cited by this paper
• Supplemental materials for: Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis

  2013cited by this paper
• The impact of false-positive newborn screening results on families: a qualitative study

  2012cited by this paper
• Evaluation and long-term follow-up of infants with inborn errors of metabolism identified in an expanded screening programme.

  2011cited by this paper
• Efficacy and outcome of expanded newborn screening for metabolic diseases - Report of 10 years from South-West Germany *

  2011cited by this paper
• Diagnoses of newborns and mothers with carnitine uptake defects through newborn screening.

  2010cited by this paper
• Expanded Newborn Screening: Outcome in Screened and Unscreened Patients at Age 6 Years

  2009cited by this paper
• Effect of Carnitine Deprivation on Carnitine Homeostasis and Energy Metabolism in Mice with Systemic Carnitine Deficiency

  2008cited by this paper
• Expanded newborn screening identifies maternal primary carnitine deficiency.

  2007cited by this paper
• Exclusive cardiac dysfunction in familial primary carnitine deficiency cases: a genotype–phenotype correlation

  2007cited by this paper
• Pharmacological rescue of carnitine transport in primary carnitine deficiency

  2006cited by this paper
• Phenotypic manifestations of the OCTN2 V295X mutation: Sudden infant death and carnitine‐responsive cardiomyopathy in Roma families

  2004cited by this paper
• Identification of the up- and down-regulated genes in the heart of juvenile visceral steatosis mice.

  2004cited by this paper
• Frequencies of inherited organic acidurias and disorders of mitochondrial fatty acid transport and oxidation in Germany

  2004cited by this paper
• Novel OCTN2 mutations: no genotype-phenotype correlations: early carnitine therapy prevents cardiomyopathy.

  2002cited by this paper
• Literature Reviews: Primary Systemic Carnitine Deficiency is Caused by Mutations in a Gene Encoding Sodium-Ion-Dependent Carnitine Transporter

  2001cited by this paper
• Carnitine transporter defect diagnosed by newborn screening with electrospray tandem mass spectrometry.

  2001cited by this paper
• Phenotype and genotype variation in primary carnitine deficiency

  2001cited by this paper
• Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter

  1999cited by this paper
• First prenatal diagnosis of the carnitine transporter defect.

  1996cited by this paper
• Increased expression of carnitine palmitoyltransferase I gene is repressed by administering L-carnitine in the hearts of carnitine-deficient juvenile visceral steatosis mice.

  1996cited by this paper
• Intercurrent illness in inborn errors of intermediary metabolism.

  1992cited by this paper
• Chronic cardiomyopathy and weakness or acute coma in children with a defect in carnitine uptake

  1991cited by this paper
• Primary carnitine deficiency due to a failure of carnitine transport in kidney, muscle, and fibroblasts.

  1988influential reference
• Principles and practice of screening for disease

  1968cited by this paper

• Integrating the Genomic Revolution into Newborn Screening: Current Challenges and Future Perspectives.

  2026cites this paper
• Maternal metabolic conditions identified by newborn screening.

  2025cites this paper
• An Explorative Qualitative Study of the Role of a Genetic Counsellor to Parents Receiving a Diagnosis After a Positive Newborn Bloodspot Screening

  2025cites this paper
• Newborn screening of primary carnitine deficiency: clinical and molecular genetic characteristics

  2025cites this paper
• Benefits and pitfalls in newborn screening for carnitine uptake deficiency: a 4-year single-center experience.

  2025cites this paper
• Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020–2023)

  2024cites this paper
• Incorporating Next‐Generation Sequencing as a Second‐Tier Test for Primary Carnitine Deficiency

  2024cites this paper
• Counting Conditions on Newborn Bloodspot Screening Panels in Australia and New Zealand

  2024cites this paper
• Collaborative evaluation study on 18 candidate diseases for newborn screening in 1.77 million samples

  2023cites this paper
• Newborn screening for primary carnitine deficiency: who will benefit? – a retrospective cohort study

  2023cites this paper
• Newborn Screening of Primary Carnitine Deficiency: An Overview of Worldwide Practices and Pitfalls to Define an Algorithm before Expansion of Newborn Screening in France

  2023influential citation
• A qualitative study on the perspectives of mothers who had been diagnosed with primary carnitine deficiency through newborn screening of their child

  2023influential citation
• Newborn screening for fatty acid oxidation disorders in a southern Chinese population

  2023cites this paper
• Primary carnitine deficiency: Estimation of prevalence in Chinese population and insights into newborn screening

  2023cites this paper
• Phenotypic and molecular features of Thai patients with primary carnitine deficiency

  2022cites this paper
• Introduction of a Protocol for Structured Follow-Up and Texting of Inadequate and Borderline-Positive Newborn Metabolic Screening Results

  2022cites this paper
• Introducing Newborn Screening for Severe Combined Immunodeficiency—The New Zealand Experience

  2022cites this paper
• Assessment of carnitine excretion and its ratio to plasma free carnitine as a biomarker for primary carnitine deficiency in newborns

  2022influential citation
• Functional genomics of OCTN2 variants informs protein-specific variant effect predictor for Carnitine Transporter Deficiency

  2022cites this paper
• Infantile primary carnitine deficiency: A severe cardiac presentation unresponsive to carnitine supplementation

  2022cites this paper
• Biochemical and genetic characteristics of patients with primary carnitine deficiency identified through newborn screening

  2021cites this paper
• Expanding Neonatal Bloodspot Screening: A Multi-Stakeholder Perspective

  2021cites this paper
• Newborn screening for carnitine transporter defect in Bavaria and the long-term follow-up of the identified newborns and mothers: Assessing the benefit and possible harm based on 19 ½ years of experience

  2021cites this paper
• Increased detection of primary carnitine deficiency through second-tier newborn genetic screening

  2021cites this paper
• Expanded Neonatal Bloodspot Screening Programmes: An Evaluation Framework to Discuss New Conditions With Stakeholders

  2021cites this paper
• Primary carnitine deficiency – diagnosis after heart transplantation: better late than never!

  2020cites this paper
• Expanded Screening of One Million Swedish Babies with R4S and CLIR for Post-Analytical Evaluation of Data

  2020cites this paper
• Performance of Expanded Newborn Screening in Norway Supported by Post-Analytical Bioinformatics Tools and Rapid Second-Tier DNA Analyses

  2020cites this paper
• Neonatal and carrier screening for rare diseases: how innovation challenges screening criteria worldwide

  2020cites this paper
• Impact of predictive, preventive and precision medicine strategies in epilepsy

  2020cites this paper
• Emerging Moonlighting Functions of the Branched-Chain Aminotransferase Proteins

  2020cites this paper
• Update on the treatment of vitamin B6 dependent epilepsies

  2019cites this paper
• Impact of newborn screening for very‐long‐chain acyl‐CoA dehydrogenase deficiency on genetic, enzymatic, and clinical outcomes

  2019cites this paper